News | February 25, 2022
Risk appetite key to innovation in pharma and biopharma
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
TATA MD’s OmiSure is the only test approved by the ICMR for RT-PCR detection of the Omicron variant
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
Subscribe To Our Newsletter & Stay Updated
